A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Pharmacogenetics (London)

• Publication date

  1999-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00008571-199906000-00003PMID 10471060
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity.

  2003cited by this paper
• Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.

  1997cited by this paper
• Nomenclature for human CYP2D6 alleles.

  1996cited by this paper
• A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype.

  1996cited by this paper
• CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes.

  1996cited by this paper
• Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.

  1995cited by this paper
• A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency

  1995cited by this paper
• A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype.

  1995cited by this paper
• A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine

  1994cited by this paper
• Clinical implications of genetic polymorphism in drug metabolism.

  1994cited by this paper
• Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.

  1994cited by this paper
• Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.

  1993cited by this paper
• Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

  1993cited by this paper
• Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6

  1993cited by this paper
• Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population

  1992cited by this paper
• Debrisoquine/Sparteine Hydroxylation Genotype and Phenotype: Analysis of Common Mutations and Alleles of CYP2D6 in a European Population

  1991cited by this paper
• Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations.

  1991cited by this paper
• Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.

  1991cited by this paper
• Identification of the primary gene defect at the cytochrome P450 CYP2D locus

  1990cited by this paper
• Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.

  1990cited by this paper
• Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

  1990cited by this paper
• The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.

  1990cited by this paper
• Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese

  1989cited by this paper
• The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.

  1989cited by this paper
• Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.

  1988cited by this paper
• Evidence for polymorphic oxidation of sparteine in Japanese subjects.

  1987cited by this paper
• Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

  1985cited by this paper
• A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

  1980cited by this paper
• Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

  1979cited by this paper

• Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and European Society for Pharmacogenomics a

  2021cites this paper
• Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10.

  2020cites this paper
• Effects of Tramadol Coadministration on Prothrombin Time-International Normalized Ratio in Patients Receiving Warfarin.

  2017cites this paper
• Farmacogenética del "CYP2D6" en la población argentina general y judía Ashkenazi

  2015cites this paper
• Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine

  2015cites this paper
• Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

  2014cites this paper
• The Pharmacogenomics of Cytochrome P450s: From Molecular to Clinical Application

  2014cites this paper
• Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations

  2014cites this paper
• Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies

  2013cites this paper
• Pharmacogenomics of CYP 2 D 6 : Molecular Genetics , Interethnic Differences and Clinical Importance

  2012cites this paper
• Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance.

  2012cites this paper
• Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters.

  2012cites this paper
• In vitro assessment of the allelic variants of cytochrome P450.

  2012cites this paper
• Drug interaction (22. opioid-drug interactions)

  2011cites this paper
• Frequencies of Three CYP2D6 Nonfunctional Alleles (CYP2D6*3, *4, and *6) Within an Iranian Population (Mazandaran)

  2011influential citation
• Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.

  2010cites this paper
• Pharmacogenetics of cytochrome P450 (CYP) in the elderly.

  2010cites this paper
• Comparison of plasma levels between oral solution and fine granule dosage forms of risperidone

  2009cites this paper
• Discovery of Novel Functional Variants and Extensive Evaluation of CYP2D6 Genetic Polymorphisms in Koreans

  2009cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009influential citation
• Einfluss des Cytochrom P450 Enzyms CYP2D6 auf den Metabolismus von Methadon

  2008cites this paper
• Do Single Nucleotide Polymorphisms in Xenobiotic Metabolizing Genes Determine Breast Cancer Susceptibility and Treatment Outcomes?

  2008cites this paper
• Impact of CYP2D6*10 on recurrence‐free survival in breast cancer patients receiving adjuvant tamoxifen therapy

  2008cites this paper
• Dose-Dependent Effect of the CYP2D6 Genotype on the Steady-state Fluvoxamine Concentration

  2008cites this paper
• Functional Characterization of 17 CYP2D6 Allelic Variants (CYP2D6.2, 10, 14A–B, 18, 27, 36, 39, 47–51, 53–55, and 57)

  2008influential citation
• Clinical pharmacogenetics and potential application in personalized medicine.

  2008cites this paper
• Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.

  2007cites this paper
• Genetic testing for pharmacogenetics and its clinical application in drug therapy.

  2006cites this paper
• Two novel single nucleotide polymorphisms (SNPs) of the CYP2D6 gene in Japanese individuals.

  2005cites this paper
• CYP1A2 phenotype and genotype in a population from the Carboniferous Region of Coahuila, Mexico.

  2005cites this paper
• Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans

  2005cites this paper
• Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1.

  2004cites this paper
• Potential Role of Cerebral Cytochrome P450 in Clinical Pharmacokinetics

  2004cites this paper
• A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients.

  2004cites this paper
• Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease

  2004cites this paper
• Drug-Metabolizing Enzymes and P-Glycoprotein

  2004cites this paper
• Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19.

  2003cites this paper
• Effects of CYP2D6 Genotypes on Plasma Concentrations of Risperidone and Enantiomers of 9‐Hydroxyrisperidone in Japanese Patients with Schizophrenia

  2003cites this paper
• Two novel haplotypes of CYP2D6 gene in a Japanese population.

  2003cites this paper
• Gender, ethnicity and genetics in cardiovascular disease: part 1: Basic principles.

  2003cites this paper
• Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese population.

  2003cites this paper
• Effects of Various CYP2D6 Genotypes on the Steady-State Plasma Concentrations of Risperidone and Its Active Metabolite, 9-Hydroxyrisperidone, in Japanese Patients With Schizophrenia

  2003cites this paper
• A CYP2D6 Phenotype-Genotype Mismatch in Japanese Psychiatric Patients

  2003cites this paper
• New allelic arrangement CYP2D6*36 x 2 found in a Japanese poor metabolizer of debrisoquine.

  2002cites this paper
• Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of lung cancer

  2002cites this paper
• ROLE OF HUMAN CYTOCHROME P450 (CYP) IN THE METABOLIC ACTIVATION OF NITROSAMINE DERIVATIVES: APPLICATION OF GENETICALLY ENGINEERED SALMONELLA EXPRESSING HUMAN CYP

  2002cites this paper
• Susceptibilités génétiques et expositions professionnelles

  2001cites this paper
• Genetic polymorphisms in drug-metabolizing enzymes and drug targets.

  2001cites this paper
• CYP2D6 polymorphism and the presence of anti-LKM-1 in patients with chronic hepatitis C.

  2000cites this paper
• Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer.

  2000cites this paper
• High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5' nuclease chain reaction assay.

  2000cites this paper
• Genetic polymorphisms of biotransformation enzymes: allele frequencies in the population of the Czech Republic.

  2000cites this paper
• Chapter 23. Pharmacogenomics

  2000cites this paper
• Pharmacogenomics and Personalized Medicine Dovepress Clinical Significance of Pharmacogenomic Studies in Tardive Dyskinesia Associated with Patients with Psychiatric Disorders

  year unknowncites this paper